

**Data Sheet**

<b>NAME :</b>	vT173
<b>REPOSITORY REFERENCE :</b>	ARP2037
<b>PROVIDED:</b>	1 vial cell-free virus (NYCBH), 1 x 10 <sup>10</sup> pfu/ml
<b>DESCRIPTION:</b>	The HIV-1 <sub>94UG114.1</sub> <i>env</i> gene was modified to introduce silent mutations to remove two internal T <sub>5</sub> NT sequences encoding vaccinia virus early transcription termination sequences. A plasmid containing the vaccinia K1L gene and the modified <i>env</i> gene under control of the vaccinia 40K promoter was transfected into RK <sub>13</sub> cells infected with vAbT33, a K1L-, M2L-, LacZ <sup>+</sup> derivative of the NYCBH strain that cannot grow on RK <sub>13</sub> cells due to the absence of the K1L host range gene. The resultant recombinant vT173 was isolated and purified in RK <sub>13</sub> cells.
<b>SPECIAL CHARACTERISTICS :</b>	Cells infected with vT173 express the HIV-1 <sub>94UG114.1</sub> <i>env</i> gene (subtype D).
<b>STERILITY:</b>	Negative for bacteria, fungi, and mycoplasma.
<b>STORAGE :</b>	-70°C
<b>SOURCE :</b>	Therion Biologics Corporation, in collaboration with Dr. Feng Gao and Dr. Beatrice Hahn. Viruses expanded by Quality Biological, Inc. (courtesy of NIH AIDS Research and reference Reagent Programme.)

**NOTE:**

Limited to 1 aliquot per laboratory. Recipients must maintain their own stocks according to the procedures described on the data sheet. Available only for non-commercial use. Requests from commercial institutions should be directed to Dr. Gail Mazzara, Vice President, R & D, Therion Biologics Corp., 76 Rogers St., Cambridge, MA 02142.

**ACKNOWLEDGEMENTS :**

Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website at <http://www.nibsc.ac.uk/spotlight/aidsreagent/index.html> in the "Acknowledgements" section.

Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be electronically or as a paper copy)